ArticleHepatic medicine : evidence and research2026
Efficacy and Metabolic Effects of Pegylated Interferon α-2b versus Nucleos(T)ide Analogues in Patients with Chronic Hepatitis B and Concomitant Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Study.
Article in Hepatic medicine : evidence and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the Study: CHB and MASLD are increasingly prevalent coexisting conditions that accelerate liver fibrosis progression and increase hepatocellular carcinoma risk. This study aimed to compare the antiviral efficacy and metabolic effects of PEG-IFNα-2b versus nucleos(t)ide analogues (NAs) in patients with the CHB-MASLD comorbidity. Methods: This retrospective study enrolled 174 biopsy-confirmed CHB-MASLD patients treated at Xiamen Hospital of Traditional Chinese Medicine between July 2019 and July 2024. Patients received either PEG-IFNα-2b (n = 87) or NAs (n = 87) for ≥ 48 weeks. Primary outcomes included HBsAg seroclearance and quantitative reduction. Metabolic parameters, liver stiffness measurement (LSM), and controlled attenuation parameter (CAP) were assessed at baseline, 24 weeks, and 48 weeks. Multivariate linear regression was performed to evaluate treatment effects on metabolic changes, adjusting for baseline values, age, sex, HBeAg status, and BMI. Results: At 48 weeks, PEG-IFNα-2b achieved significantly higher HBsAg seroclearance rates compared with NAs ( Conclusion: In CHB-MASLD patients, PEG-IFNα-2b provides better virological response and favorable metabolic modulation, supporting it may represent a promising treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.